Within the biotech sector, Incyte (INCY) demonstrates robust long-term growth potential through its diversified pipeline, strong cash flow, and efficient capital deployment. Meanwhile, TG Therapeutics (TGTX) benefits from the rapid commercial expansion of Briumvi and its high-profit-margin profile, coupled with its appeal as a potential M&A target. Both companies present distinctive investment value in the current biotechnology market.
Both stocks have delivered strong returns this year. Incyte’s share price has risen more than 17% year-to-date, while TG Therapeutics has rallied nearly 90% so far in 2026.
Incyte’s financial strength is primarily supported by its JAK inhibitor Jakafi, used for rare blood cancers, and its rapidly growing dermatological cream Opzelura, approved for vitiligo and atopic dermatitis. In the first quarter, Jakafi generated sales of $758 million, a 7% increase year-over-year, while Opzelura posted $143 million in revenue, up 20% year-over-year. Total company revenue reached $1.27 billion, rising 21% year-over-year, with earnings per share (EPS) of $1.47, an 83.7% increase from the first quarter of 2025. Adjusted EPS came in at $1.81, exceeding the consensus analyst estimate of $1.34.
Incyte has actively deployed free cash flow through acquisitions to reduce concentration risk. Its recent $1.25 billion acquisition of Vega Therapeutics added VGA039, a subcutaneous investigational therapy for bleeding disorders in Phase 3 development, expanding the company’s footprint into non-oncology hematology and adding a potential first-in-class multi-billion-dollar drug to its late-stage pipeline. The company has ten Phase 3 studies underway and expects four new oncology and immunology drugs to receive regulatory approval by early 2027. Among these, Monjuvi performed well in a Phase 3 trial for first-line combination therapy in diffuse large B-cell lymphoma; povorcitinib is being studied for hidradenitis suppurativa and non-segmental vitiligo; and the company holds high expectations for INCB161734 in pancreatic ductal adenocarcinoma.
Incyte demonstrates exceptional capital efficiency, with a return on equity exceeding 30%, reflecting management’s ability to convert shareholder investment and cash reserves into tangible profitability.
TG Therapeutics’ growth is primarily driven by Briumvi, an intravenous infusion therapy for relapsing forms of multiple sclerosis. Management recently raised full-year revenue guidance to $925 million, with the drug generating $194.8 million in U.S. sales alone in the first quarter. The company also increased Briumvi’s full-year sales guidance to a range of $885 million to $900 million. Briumvi is currently in a Phase 3 trial as a self-administered subcutaneous formulation for multiple sclerosis, and is also being studied for treatment-resistant schizophrenia in patients with inadequate response to standard antipsychotics, as well as a subcutaneous formulation for myasthenia gravis, a chronic rare autoimmune neuromuscular disease.
TG Therapeutics maintains a gross margin of approximately 83%. First-quarter revenue reached $204.9 million, a 69.5% increase year-over-year, while EPS stood at $0.12, representing a 300% increase compared to the prior-year period. Given the recent wave of multi-billion-dollar M&A transactions in the biotech space, the company’s highly profitable, single-blockbuster commercial model positions it as an attractive high-return target for large pharmaceutical companies seeking to acquire established neurology franchises. Potential acquirers include multiple major pharmaceutical companies with established presences in neurology and immunology.
